|
Horizon Diagnostics (HorizonDx), a division of Horizon Discovery, a provider of research tools to support the development and prescription of personalized medicines, announced it has signed a strategic partnership agreement with UK NEQAS. The partnership will focus on the development of genetically defined reference standards for novel lung cancer biomarkers. HorizonDx is the first company to provide human genomic reference standards containing defined allelic ratios, offering an unprecedented level of control to the diagnostics industry. The reference materials will be used to minimise variability involved in FISH and IHC based diagnostic testing, to guide prescription of targeted cancer therapies.
UK NEQAS (the UK National External Quality Assessment Service) is a leader in diagnostic proficiency assessment. Under the terms of the agreement, UK NEQAS ICC will receive an exclusive license to distribute reference standards related to certain lung cancer biomarkers in the UK and in Europe for the sole purpose of proficiency testing within its quality assessment program.
Dr. Paul Morrill, commercial director, Horizon Discovery, commented: "Newly discovered mutations are rapidly shaping how and when novel cancer therapies are prescribed, and quality assurance for diagnostics is a key factor in the prescription of these therapies. Through this partnership with UK NEQAS, we look forward to seeing our genetically defined reference standards adopted in proficiency schemes and as batch controls, ultimately helping to improve the accuracy of diagnostic testing for patients."
www.horizondx.com, www.ukneqas.org.uk/
|